FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Condition:   Solid Tumor, Adult
Interventions:   Drug: FT538;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Combination Product: Monoclonal antibody – Dose Escalation;   Combination Product: Monoclonal antibody – Dose Expansion
Sponsor:   Fate Therapeutics
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 13, 2022Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments